Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active then Sham Treatment Clear all
Completed Phase 1 Interventional Results available

Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

NCT01682811
View directory record Official record
Conditions
Neurofibromatoses
Interventions
Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 14, 2026, 2:20 PM EDT
Not listed Phase 4 Interventional

Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension

NCT01468571
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 14, 2026, 2:20 PM EDT
Recruiting Phase 3 Interventional

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099
View directory record Official record
Conditions
Crohn's Disease, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 2:20 PM EDT
Recruiting Phase 2Phase 3 Interventional

Exercise and Intranasal Insulin in Type 2 Diabetes

NCT07675499
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Sensitivity/Resistance, Cognition, Brain Blood Flow
Interventions
Intranasal Insulin, Intranasal Placebo, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
New Brunswick, New Jersey • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 14, 2026, 2:20 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity

NCT04427709
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis, Knee
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept or Placebo (both as IV & SC solution), Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

NCT01194414
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
54
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 4 Interventional

Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus

NCT04951206
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
Fractionated CO2-laser, Clobetasol Propionate 0.05% Ointment
Device · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study

NCT02676466
View directory record Official record
Conditions
Inflammation
Interventions
Omega-3 fish oil, Losartan, Corn Oil (Fish oil Placebo), Cellulose Based (Losartan Placebo)
Dietary Supplement · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
70 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Not applicable Interventional

Impact of Resistance Training-Protein Supplementation on Lean Muscle Mass in Childhood Cancer Survivors

NCT02501460
View directory record Official record
Conditions
Cancer
Interventions
Educational handouts, Resistance training, Supplementation, Placebo
Other · Dietary Supplement
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 44 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 14, 2026, 2:20 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

NCT03318523
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Placebo, BIIB054
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 2Phase 3 Interventional

Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension

NCT00581607
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Bosentan, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
New York, New York • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Not applicable Interventional

An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD

NCT02229903
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Active DTMS Treatment, Sham Treatment
Device
Lead sponsor
Brainsway
Industry
Eligibility
22 Years to 68 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 14, 2026, 2:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mitigating the Disinhibiting Effects of Alcohol With Transcranial Magnetic Stimulation

NCT07188376
View directory record Official record
Conditions
Alcohol Risk Behaviors
Interventions
Intermittent Theta Burst Stimulation, Continuous Theta Burst Stimulation, Sham Transcranial Magnetic Stimulation
Device
Lead sponsor
Michael J. Wesley, PhD
Other
Eligibility
21 Years to 29 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 14, 2026, 2:20 PM EDT
Active, not recruiting Not applicable Interventional

Radiofrequency Ablation After Total Knee Arthroplasty

NCT05473663
View directory record Official record
Conditions
Chronic Knee Pain
Interventions
Radiofrequency Ablation, Sham
Device
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 2 Interventional

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

NCT01279590
View directory record Official record
Conditions
Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions
PPD10558, Atorvastatin, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
67
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2011 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Not applicable Interventional

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

NCT00826059
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Active Sphenopalatine Ganglion (SPG) Stimulation, Sham Sphenopalatine Ganglion (SPG) Stimulation
Device
Lead sponsor
BrainsGate
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
7
States / cities
Sarasota, Florida • Winfield, Illinois • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

NCT01369355
View directory record Official record
Conditions
Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
Interventions
Placebo SC, Placebo IV, Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
77
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

NCT04876391
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 14, 2026, 2:20 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

NCT07044297
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
4,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis

NCT03998488
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Fecal Microbiota Transplantation, Psyllium Husk Powder
Drug · Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 14, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Results available

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

NCT04126603
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebos
Drug
Lead sponsor
Sabyasachi Sen
Other
Eligibility
20 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 14, 2026, 2:20 PM EDT
Recruiting Not applicable Interventional

Enhancing Language Function in Primary Progressive Aphasia

NCT04920318
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
tDCS + language therapy, sham TDCS + language therapy
Combination Product
Lead sponsor
University of Arizona
Other
Eligibility
45 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 14, 2026, 2:20 PM EDT